Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
460-04-009 ISMRM Abstract

Predictive value of functional tumor volume and ctDNA for breast cancer response to neoadjuvant therapy: a multi-center study

Primary: Body - Breast
Secondary: Analysis Methods - Classification and Prediction
460-04-009 · Breast MRI Sequences and Clinical Developments · Tuesday, 12 May, 2:35 PM–3:30 PM · Digital Posters Row A
Keywords: Treatment Response Neoadjuvant therapy Breast MRI CtDNA Cancer Subtypes
Accepted
Wen Li 1, Mark Magbanua2, Natsuko Onishi1,2,3,4, Nu N Le1, Lisa Wilmes1,3,5, Teffany Joy Bareng1, Matthew Gibbons1,2, Pouya Metanat1, Elissa Price1, Bonnie Joe1,2,3,4,5, John Kornak1,6, Denise Wolf7, Keli Santos-Parker8, Christina Yau2,8, Barbara LeStage9, I-SPY 2 Investigator Network10, I-SPY2 Imaging Working Group, Hope Rugo11, Angela DeMichele12, Laura J Esserman8, Laura van 't Veer7, Nola Hylton1,2,5
1Department of Radiology and Biomedical Imaging, University Of California, San Francisco (UCSF), United States of America
2University Of California, San Francisco (UCSF), United States of America
3Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America
4University of California San Francisco, San Francisco, United States of America
5Department of Radiology, University of California San Francisco, San Francisco, United States of America
6Department of Epidemiology & Biostatistics, University Of California, San Francisco (UCSF), United States of America
7Department of Laboratory Medicine, University Of California, San Francisco (UCSF), United States of America
8Department of Surgery, University Of California, San Francisco (UCSF), United States of America
9I-SPY 2 Advocacy Group, San Francisco, United States of America
10Quantum Leap Healthcare Collaborative, San Francisco, United States of America
11Division of Hematology/Oncology, City of Hope Comprehensive Cancer Center, United States of America
12Department of Hematology/Oncology, University of Pennsylvania, Philadelphia, United States of America
Presenting Author: Wen Li

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Magbanua, M. J. M. et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell 41, 1091–1102 (2023). doi: 10.1016/j.ccell.2023.04.008. [doi]
2. Li, W. et al. MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer. Tomography 11, (2025). doi: 10.3390/tomography11030026. [doi]
3. Hylton, N. M. et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology 263, 663–72 (2012). doi: 10.1148/radiol.12110748. [doi]
4. Magbanua, M. et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer 7, (2021). doi: 10.1038/s41523-021-00239-3. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/460-04-009